Prigozin Ayelet, Uziely Beatrice, Musgrave Catherine F
Meuhedet Sick Fund and School of Nursing, Hadassah Hebrew University, Jerusalem, Israel.
Oncol Nurs Forum. 2010 Nov;37(6):E411-8. doi: 10.1188/10.ONF.E411-E418.
PURPOSE/OBJECTIVES: To examine symptom severity's relationship to symptom interference, education, age, marital status, and type of chemotherapy treatment in Israeli women with stage I or II breast cancer.
Cross-sectional, descriptive, correlational design.
Hadassah University Hospital's oncology daytime care unit in Israel.
51 women with stage I or II breast cancer who were receiving an adjuvant chemotherapy protocol that included doxorubicin.
Women receiving adjuvant chemotherapy were given the M.D. Anderson Symptom Inventory (MDASI), a modified version of the Breast Cancer Prevention Trial Hot Flashes Subscale (BCPT-HFS), and a demographic and treatment questionnaire to assess their symptoms toward the end of their chemotherapy treatment.
Symptom severity, symptom interference, education, age, marital status, and type of chemotherapy treatment.
The most frequent and severe symptoms were fatigue, sleep disturbance, and drowsiness. The MDASI symptom severity total scores were positively correlated with total scores of interference with activities of daily life, with most individual symptoms being significantly related to the total interference scores. The strongest relationships were found with fatigue, distress, and sadness. Education was inversely related to the MDASI general symptom severity total scores; age was inversely related to the BCPT-HFS total scores. Patients who received treatment with doxorubicin plus cyclophosphamide or doxorubicin, cyclophosphamide, plus fluorouracil had greater symptom severity than those who received doxorubicin plus cyclophosphamide followed by paclitaxel and had their symptoms evaluated after receiving paclitaxel.
Increased symptom severity disrupts daily function and life in women with breast cancer.
Evidence-based symptom profiles for different chemotherapy protocols are needed.
目的/目标:探讨以色列I期或II期乳腺癌女性患者症状严重程度与症状干扰、教育程度、年龄、婚姻状况及化疗治疗类型之间的关系。
横断面、描述性、相关性设计。
以色列哈达萨大学医院肿瘤日间护理单元。
51例接受包含阿霉素的辅助化疗方案的I期或II期乳腺癌女性患者。
接受辅助化疗的女性患者在化疗治疗接近尾声时,接受了MD安德森症状量表(MDASI)、乳腺癌预防试验潮热分量表(BCPT-HFS)的修订版以及一份人口统计学和治疗问卷,以评估她们的症状。
症状严重程度、症状干扰、教育程度、年龄、婚姻状况及化疗治疗类型。
最常见且严重的症状是疲劳、睡眠障碍和嗜睡。MDASI症状严重程度总分与日常生活活动干扰总分呈正相关,大多数个体症状与总干扰得分显著相关。与疲劳、痛苦和悲伤的关系最为密切。教育程度与MDASI总体症状严重程度总分呈负相关;年龄与BCPT-HFS总分呈负相关。接受阿霉素加环磷酰胺或阿霉素、环磷酰胺加氟尿嘧啶治疗的患者,其症状严重程度高于接受阿霉素加环磷酰胺后再接受紫杉醇治疗且在接受紫杉醇后评估症状的患者。
症状严重程度增加会干扰乳腺癌女性患者的日常功能和生活。
需要针对不同化疗方案的循证症状概况。